Leveraging speech and artificial intelligence to screen for early Alzheimer's disease and amyloid beta positivity.

Fristed, Emil; Skirrow, Caroline; Meszaros, Marton; Lenain, Raphael; Meepegama, Udeepa; Papp, Kathryn V; Ropacki, Michael; Weston, Jack

Fristed, Emil; Skirrow, Caroline; Meszaros, Marton; Lenain, Raphael; Meepegama, Udeepa; Papp, Kathryn V; Ropacki, Michael; Weston, Jack.

Afiliación

Fristed E; Novoic Ltd, London, N1 7EU, UK.
Skirrow C; Novoic Ltd, London, N1 7EU, UK.
Meszaros M; Novoic Ltd, London, N1 7EU, UK.
Lenain R; Novoic Ltd, London, N1 7EU, UK.
Meepegama U; Novoic Ltd, London, N1 7EU, UK.
Papp KV; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA.
Ropacki M; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, 02114, USA.
Weston J; Strategic Global Research & Development, Temecula, California, 94019, USA.

Brain Commun ; 4(5): fcac231, 2022.

Article en En | MEDLINE | ID: mdl-36381988

Palabras clave

Alzheimer's disease; MCI (mild cognitive impairment); artificial intelligence; machine learning; speech

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Screening_studies Idioma: En Revista: Brain Commun Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google